Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease

Launched by UNIVERSITY OF AARHUS · Jun 19, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new type of imaging called hyperpolarized 129-Xenon MRI to help doctors identify and monitor early signs of lung scarring, known as pulmonary fibrosis, in patients with progressive fibrosing interstitial lung disease. The goal is to understand how this condition affects the lungs and the heart, and to see how certain risk factors might influence the effectiveness of treatments designed to slow down the progression of the disease.

To participate in this study, individuals need to be between 18 and 90 years old and have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another type of fibrotic interstitial lung disease while being prescribed antifibrotic medications. They must also be able to understand the study and give consent. Participants will undergo non-invasive MRI scans to gather important information about their condition. It's important to note that certain medical devices or conditions may prevent someone from being eligible for this study, so potential participants should discuss their individual health situations with their doctors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed signed consent
• • Age 18-90
• • Pre-menopausal women must be confirmed non-pregnant by an onsite test.
• • Patients diagnosed with IPF or fibrotic ILD who fulfills PPF criteria, and are prescribed antifibrotic treatment.
• • Cognitively able to understand and participate in the study
• Exclusion Criteria:
• * Contraindications for MRI:
• • Pacemaker, neurostimulator or cochlear implant
• • Metal foreign bodies such as fragments and irremovable piercings
• • Unsafe medical implants (safety of heart valves, hips and the like must be confirmed)
• • Intrathoracic clips or coils
• • Cardiac pacemakers
• • Claustrophobia
• • Largest circumference including arms \> 160 cm
• • Contraindications to gadolinium contrast
• • eGFR \< 30 mL/min/1.73m2
• • Previous adverse reactions to gadolinium
• • Overlapping emphysemic disease where the emphysema-component outweighs the fibrosis
• • Unable to perform breath-hold of minimum 20 seconds.
• • Allergy to Xenon
• • Breast feeding
• • Evidence of ongoing respiratory infections at time of MR examinations